BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37201729)

  • 1. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.
    Baert L; Manfroi B; Quintero M; Chavarria O; Barbon PV; Clement E; Zeller A; Van Kuppevelt T; Sturm N; Moreaux J; Tveita A; Bogen B; McKee T; Huard B
    Matrix Biol; 2023 Jun; 120():60-75. PubMed ID: 37201729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
    Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
    Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
    Ren Z; Spaargaren M; Pals ST
    Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
    Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Hs3st3a1 or Hs3st3b1 enzymes alters heparan sulfate to reduce epithelial morphogenesis and adult salivary gland function.
    Patel VN; Pineda DL; Berenstein E; Hauser BR; Choi S; Prochazkova M; Zheng C; Goldsmith CM; van Kuppevelt TH; Kulkarni A; Song Y; Linhardt RJ; Chibly AM; Hoffman MP
    Matrix Biol; 2021 Sep; 103-104():37-57. PubMed ID: 34653670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
    Reijmers RM; Groen RW; Rozemuller H; Kuil A; de Haan-Kramer A; Csikós T; Martens AC; Spaargaren M; Pals ST
    Blood; 2010 Jan; 115(3):601-4. PubMed ID: 19965677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.
    Anower-E-Khuda F; Singh G; Deng Y; Gordts PLSM; Esko JD
    Glycobiology; 2019 Jul; 29(8):582-592. PubMed ID: 31094413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments.
    Delcommenne M; Klingemann HG
    Hum Antibodies; 2012; 21(1-2):29-40. PubMed ID: 22885958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
    Stewart MD; Ramani VC; Sanderson RD
    J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-sulfation of heparan sulfate is critical for syndecan-4-mediated podocyte cell-matrix interactions.
    Sugar T; Wassenhove-McCarthy DJ; Orr AW; Green J; van Kuppevelt TH; McCarthy KJ
    Am J Physiol Renal Physiol; 2016 May; 310(10):F1123-35. PubMed ID: 26936875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
    Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
    Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
    Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
    Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains.
    Kato M; Wang H; Bernfield M; Gallagher JT; Turnbull JE
    J Biol Chem; 1994 Jul; 269(29):18881-90. PubMed ID: 8034644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
    Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
    J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor.
    Deepa SS; Yamada S; Zako M; Goldberger O; Sugahara K
    J Biol Chem; 2004 Sep; 279(36):37368-76. PubMed ID: 15226297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
    Ramani VC; Sanderson RD
    Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior.
    Sanderson RD; Turnbull JE; Gallagher JT; Lander AD
    J Biol Chem; 1994 May; 269(18):13100-6. PubMed ID: 8175735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndecan-1: a dynamic regulator of the myeloma microenvironment.
    Sanderson RD; Yang Y
    Clin Exp Metastasis; 2008; 25(2):149-59. PubMed ID: 18027090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.